Arca
Skip to content

BRIXADI (buprenorphine extended-release): Complete Response Letter

A complete response letter is FDA's decision not to approve an application as submitted. See NDA 210136's history or Braeburn Pharmaceuticals's company page.

On Jan 19, 2018, FDA declined to approve BRIXADI (buprenorphine extended-release) (NDA 210136) from Braeburn Pharmaceuticals Inc. in its present form, citing clinical/statistical, nonclinical, product quality. The application was later approved.

  • Letter date: Jan 19, 2018
  • Application: NDA 210136
  • Since then: Approved

What FDA Cited

FDA's own section headings in the letter; each finds other letters citing it

Clinical/statisticalNonclinicalProduct qualityIndication and usageDosage and administrationInstructions for useWarnings and precautionsClinical trials experienceRisk evaluation and mitigation strategy requirements

The Letter

Text from openFDA

1. There are insufficient clinical data | Information needed to resolve deficiency Provide additional data ©® or withdraw it from the application. 2. The submitted clinical datasets were found to include a number of discrepancies and. errors, which you have de...… openFDA did not return the full text just now. Open it in the letter search.

Other Letters on This Application

Record

Company
Braeburn Pharmaceuticals Inc.
Application
NDA 210136
Status in openFDA
Approved
Review division
Office of Drug Evaluation II

FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.